```
=> d his

     (FILE 'HOME' ENTERED AT 18:28:32 ON 13 JUN 2004)

     FILE 'MEDLINE, BIOSIS' ENTERED AT 18:28:48 ON 13 JUN 2004
L1            0 S PRO7170
L2         3446 S GLUCOSE (L) FATTY ACID? (L) UPTAKE
L3        17962 S (GLUCOSE OR FATTY ACID?) (W) UPTAKE
L4          468 S GLUCOSE (L) FATTY ACID? (L) UPTAKE (L) SKELETAL MUSCLE
L5          277 DUP REM L4 (191 DUPLICATES REMOVED)
L6          238 S L5 AND PY<2003
L7          386 S (ASHKENAZI, A?)/AU
L8            0 S L6 AND L7
L9            0 S EXMAD
```

```
XX
PT   PRO polynucleotides used to produce polypeptides used to target
PT   bioactive molecules such as toxins, radiolabels or antibodies, to
PT   specific cells, to cause targeted cell death -
XX
PS   Claim 12; Fig 326; 935pp; English.
XX
CC   The present invention describes human secreted and transmembrane PRO
CC   proteins. The PRO proteins have cytostatic activity. The PRO proteins
CC   can be used for targeted delivery of bioactive molecules, such as
CC   toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC   sequences, and their fragments, can be used as hybridisation probes, in
CC   chromosomal and gene mapping, and in the generation of anti-sense RNA
CC   and DNA. They may also be used to produce transgenic animals which are
CC   used to develop and screen therapeutically useful reagents. The PRO
CC   nucleotide and protein sequence can be used for tissue typing and in
CC   treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC   AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC   in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC   AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC   sequences given in the exemplification of the present invention.
XX
SQ   Sequence   482 AA;

  Query Match           100.0%;  Score 2429;  DB 22;  Length 482;
  Best Local Similarity  100.0%;  Pred. No. 1e-148;
  Matches  482;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTL 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTL 60

Qy         61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPE 120

Qy        121 GAGMTTVQTITGSDPEEAIFDTLCTDDSSEEAKTLTMDILTLAHTSTEAKGLSSESSASS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 GAGMTTVQTITGSDPEEAIFDTLCTDDSSEEAKTLTMDILTLAHTSTEAKGLSSESSASS 180

Qy        181 DGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSWSPGSDVTLLAE 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 DGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSWSPGSDVTLLAE 240

Qy        241 ALVTVTNIEVINCSITEIETTTSSIPGASDIDLIPTEGVKASSTSDPPALPDSTEAKPHI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ALVTVTNIEVINCSITEIETTTSSIPGASDIDLIPTEGVKASSTSDPPALPDSTEAKPHI 300

Qy        301 TEVTASAETLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLSGALVTVSRNPLE 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TEVTASAETLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLSGALVTVSRNPLE 360

Qy        361 ETSALSVETPSYVKVSGAAPVSIEAGSAVGKTTSFAGSSASSYSPSEAALKNFTPSETPT 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 ETSALSVETPSYVKVSGAAPVSIEAGSAVGKTTSFAGSSASSYSPSEAALKNFTPSETPT 420

Qy        421 MDIATKGPFPTSRDPLPSVPPTTTNSSRGTNSTLAKITTSAKTTMKPQQPRPRLPGRGRP 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 MDIATKGPFPTSRDPLPSVPPTTTNSSRGTNSTLAKITTSAKTTMKPQQPRPRLPGRGRP 480

Qy        481 QT 482
              ||
Db        481 QT 482


RESULT 4
AAB27225
ID   AAB27225 standard; Protein; 482 AA.
XX
AC   AAB27225;
XX
DT   27-MAR-2001  (first entry)
XX
DE   Human EXMAD-3 SEQ ID NO: 3.
XX
KW   Extracellular matrix and adhesion-asscociated protein; EXMAD; cancer;
KW   inflammation; reproductive disorder; cardiovascular disorder;
KW   immune disorder; musculoskeletal disorder; developmental disorder;
KW   gastrointestinal disorder; cell proliferation disorder.
XX
OS   Homo sapiens.
XX
PN   WO200068380-A2.
XX
PD   16-NOV-2000.
XX
PF   10-MAY-2000; 2000WO-US12811.
XX
PR   11-MAY-1999;   99US-0133643.
PR   23-AUG-1999;   99US-0150409.
XX
PA   (INCY-) INCYTE GENOMICS INC.
XX
PI   Bandman O,  Hillman JL,  Tang YT,  Lal P,  Yue H,  Baughn MR,  Lu DAM;
PI   Azimzai Y;
XX
DR   WPI; 2001-007395/01.
DR   N-PSDB; AAC66892.
XX
PT   Isolated polynucleotide encoding extracellular matrix or
PT   adhesion-associated protein (EXMAD) useful for diagnosing, treating, or
PT   preventing disorders associated with expression of EXMAD such as
PT   proliferative, immune and genetic disorders -
XX
PS   Claim 1; Page 89-90; 129pp; English.
XX
CC   The present invention provides the protein and coding sequences for 25
CC   novel extracellular matrix and adhesion-associated proteins (EXMADs).
CC   These are designated EXMAD-1, EXMAD-2, EXMAD-3, EXMAD-4, EXMAD-5,
CC   EXMAD-6, EXMAD-7, EXMAD-8, EXMAD-9, EXMAD-10, EXMAD-11, EXMAD-12,
CC   EXMAD-13, EXMAD-14, EXMAD-15, EXMAD-16, EXMAD-17, EXMAD-18, EXMAD-19,
CC   EXMAD-20, EXMAD-21,  EXMAD-22, EXMAD-23, EXMAD-24 and EXMAD-25. They are
CC   useful in the prevention and treatment of cancers, cell proliferation,
CC   cardiovascular, reproductive, immune, musculoskeletal, developmental and
CC   gastrointestinal disorders and inflammation.
XX
SQ   Sequence   482 AA;

  Query Match           100.0%;  Score 2429;  DB 22;  Length 482;
  Best Local Similarity  100.0%;  Pred. No. 1e-148;
  Matches  482;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTL 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTL 60

Qy         61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPE 120

Qy        121 GAGMTTVQTITGSDPEEAIFDTLCTDDSSEEAKTLTMDILTLAHTSTEAKGLSSESSASS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 GAGMTTVQTITGSDPEEAIFDTLCTDDSSEEAKTLTMDILTLAHTSTEAKGLSSESSASS 180

Qy        181 DGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSWSPGSDVTLLAE 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 DGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSWSPGSDVTLLAE 240

Qy        241 ALVTVTNIEVINCSITEIETTTSSIPGASDIDLIPTEGVKASSTSDPPALPDSTEAKPHI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ALVTVTNIEVINCSITEIETTTSSIPGASDIDLIPTEGVKASSTSDPPALPDSTEAKPHI 300

Qy        301 TEVTASAETLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLSGALVTVSRNPLE 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TEVTASAETLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLSGALVTVSRNPLE 360
```

```
Qy        361 ETSALSVETPSYVKVSGAAPVSIEAGSAVGKTTSFAGSSASSYSPSEAALKNFTPSETPT 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 ETSALSVETPSYVKVSGAAPVSIEAGSAVGKTTSFAGSSASSYSPSEAALKNFTPSETPT 420

Qy        421 MDIATKGPFPTSRDPLPSVPPTTTNSSRGTNSTLAKITTSAKTTMKPQQPRPRLPGRGRP 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 MDIATKGPFPTSRDPLPSVPPTTTNSSRGTNSTLAKITTSAKTTMKPQQPRPRLPGRGRP 480

Qy        481 QT 482
              ||
Db        481 QT 482


RESULT 5
ABU72052
ID   ABU72052 standard; Protein; 482 AA.
XX
AC   ABU72052;
XX
DT   11-JUN-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO7170.
XX
KW   Human; secreted and transmembrane polypeptide; PRO;
KW   fibroblast growth factor receptor; PRO533; PRO301; PRO187; PRO337;
KW   PRO1411; PRO10096; PRO246; PRO6307; PRO6003; FGFR-3; FGFR-4; FGFR-1;
KW   FGFR-2; PRO6004; PRO4356; PRO2630; PRO265; PRO951; bioactive molecule;
KW   toxin; radiolabel; antibody; cell death; chromosome mapping;
KW   gene mapping; transgenic animal; knockout animal; gene therapy;
KW   tissue typing.
XX
OS   Homo sapiens.
XX
PN   US2002177165-A1.
XX
PD   28-NOV-2002.
XX
PF   01-FEB-2002; 2002US-0066500.
XX
PR   14-JUL-1998;   98WO-US14552.
PR   10-SEP-1998;   98WO-US18824.
PR   14-SEP-1998;   98WO-US19093.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   20-NOV-1998;   98WO-US24855.
PR   25-NOV-1998;   98WO-US25190.
PR   01-DEC-1998;   98WO-US25108.
PR   08-MAR-1999;   99WO-US05028.
PR   02-JUN-1999;   99WO-US12252.
PR   01-SEP-1999;   99WO-US20111.
PR   08-SEP-1999;   99WO-US20594.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   02-DEC-1999;   99WO-US28565.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000; 2000WO-US00219.
PR   18-FEB-2000; 2000WO-US04341.
PR   18-FEB-2000; 2000WO-US04342.
PR   22-FEB-2000; 2000WO-US04414.
PR   01-MAR-2000; 2000WO-US05601.
PR   02-MAR-2000; 2000WO-US05841.
PR   09-MAR-2000; 2000WO-US06471.
PR   20-MAR-2000; 2000WO-US07377.
PR   30-MAR-2000; 2000WO-US08439.
PR   15-MAY-2000; 2000WO-US13358.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   11-AUG-2000; 2000WO-US22031.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   01-DEC-2000; 2000WO-US32678.
PR   28-FEB-2001; 2001WO-US06520.
PR   30-MAY-2001; 2001WO-US17443.
PR   01-JUN-2001; 2001WO-US17800.
PR   20-JUN-2001; 2001WO-US19692.
PR   29-JUN-2001; 2001WO-US21066.
PR   09-JUL-2001; 2001WO-US21735.
PR   26-AUG-1997;   97US-056974P.
PR   17-SEP-1997;   97US-059115P.
PR   18-SEP-1997;   97US-059263P.
PR   19-SEP-1997;   97US-059588P.
PR   17-OCT-1997;   97US-062285P.
PR   24-OCT-1997;   97US-062816P.
PR   24-OCT-1997;   97US-063082P.
PR   27-OCT-1997;   97US-063329P.
PR   29-OCT-1997;   97US-063733P.
PR   21-NOV-1997;   97US-066364P.
PR   25-NOV-1997;   97US-066840P.
PR   16-DEC-1997;   97US-069694P.
PR   09-FEB-1998;   98US-074086P.
PR   09-FEB-1998;   98US-074092P.
PR   25-MAR-1998;   98US-079294P.
PR   08-APR-1998;   98US-081049P.
PR   10-AUG-1998;   98US-095998P.
PR   18-AUG-1998;   98US-097000P.
PR   09-SEP-1998;   98US-099601P.
PR   10-SEP-1998;   98US-099803P.
PR   10-SEP-1998;   98US-099811P.
PR   10-SEP-1998;   98US-099812P.
PR   17-SEP-1998;   98US-100858P.
PR   24-SEP-1998;   98US-101922P.
PR   28-OCT-1998;   98US-106032P.
PR   20-NOV-1998;   98US-109304P.
PR   23-MAR-1999;   99US-125778P.
PR   15-JUN-1999;   99US-139695P.
PR   20-JUL-1999;   99US-145070P.
PR   26-JUL-1999;   99US-145698P.
PR   17-AUG-1999;   99US-149396P.
PR   07-DEC-1999;   99US-169495P.
PR   15-NOV-2001; 2001US-0002796.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein DA,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Gurney AL,  Kljavin IJ,  Mather JP,  Napier MA,  Pan J;
PI   Paoni NF,  Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM;
PI   Wood WI,  Zhang Z;
XX
DR   WPI; 2003-328482/31.
DR   N-PSDB; ACA60494.
XX
PT   Novel secreted and transmembrane polypeptide for modulating biological
PT   activity of cell expressing the polypeptide, for identifying agonists
PT   or antagonists of polypeptide, and as molecular weight markers -
XX
PS   Claim 12; Fig 34; 254pp; English.
XX
CC   The invention describes an isolated, secreted and transmembrane
CC   polypeptide (PP), termed PRO PP or fibroblast growth factor receptor PP
CC   (I). (I) is useful for detecting PRO533, PRO301, PRO187, PRO337,
CC   PRO1411, PRO10096, PRO246, PRO6307, PRO6003, fibroblast growth factor
CC   receptor (FGFR)-3, FGFR-4, FGFR-1, FGFR-2, PRO6004, PRO4356, PRO2630,
CC   PRO265 or PRO951 polypeptide, and for linking a bioactive molecule to a
CC   cell expressing the above polypeptides. The bioactive molecule, a toxin,
CC   radiolabel or an antibody, causes cell death. PRO is useful in assays to
CC   identify other proteins or molecules involved in binding interaction.
CC   The polynucleotide (II) encoding (I) is useful in chromosome and gene
CC   mapping, in generation of antisense RNA and DNA, for generating
CC   transgenic animals or knockout animals which in turn are useful in the
CC   development and screening of therapeutically useful reagents, to
CC   construct hybridisation probes for mapping the gene which encodes the
```

```
Db        181 DGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGP 240

Qy        222 HPVITPSWSPGSDVTLLAEALVTVTNIEVINCSITEIETTTSSIPGASDIDLIPTEGVKA 281
              ||||||||||||||||||||||||||||||||||||||||||||||||||| | ||||||||
Db        241 HPVITPSWSPGSDVTLLAEALVTVTNIEVINCSITEIETTTSSIPGASDTDPIPTEGVKA 300

Qy        282 SSTSDPPALPDSTEAKPHITEVTASAETLSTAGTTESAAPHATVGTPLPTNSATEREVTA 341
              |||||||||||||||||||||||||||||||||||| ||:|||||||  ||||||
Db        301 SSTSDPPALPDSTEAKPHITEVTASAETLSTAGTTESAAPDATIGTPLPTNSTIEREVTA 360

Qy        342 PGATTLSGALVTVSRNPLEETSALSVETPSYVKVSGAAPVSIEAGSAVGKTTSFAGSSAS 401
              |||||||||| |   ||||||||||||||||||||||||||||||||||||||||||||||
Db        361 PGATTLSGALAT--GNPLEETSALSVETPSYVKVSGAAPVSIEAGSAVGKTTSFAGSSAS 418

Qy        402 SYSPSEAALKNFTPSETPTMDIATKGPFPTSRDPLPSVPPTTTNSSRGTNSTLAKITTSA 461
              |||||||||||||||| | ||||||||||||||||||||||||||||||||||||||||||
Db        419 SYSPSEAALKNFTPSETLTTDIATKGPFPTSRDPLPSVPPTTTNSSRGTNSTLAKITTSA 478

Qy        462 KTTMKPQQPRPRLPGRGRPQT 482
              ||||||    |    | || |
Db        479 KTTMKPPTATP-TTARTRPTT 498
```

RESULT 2
Q9P2I8
ID Q9P2I8 PRELIMINARY; PRT; 517 AA.
AC Q9P2I8;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Hypothetical protein KIAA1359 (Fragment).
GN KIAA1359.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX MEDLINE=20181126; PubMed=10718198;
RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes.XVI.
RT The complete sequences of 150 new cDNA clones from brain which code
RT for large proteins in vitro.";
RL DNA Res. 7:65-73(2000).
DR EMBL; AB037780; BAA92597.1; -.
KW Hypothetical protein.
FT NON_TER 1 1
SQ SEQUENCE 517 AA; 52332 MW; 6D14ABA896221DFF CRC64;

Query Match 88.4%; Score 2146.5; DB 4; Length 517;
Best Local Similarity 87.5%; Pred. No. 1.2e-108;
Matches 439; Conservative 2; Mismatches 4; Indels 57; Gaps 1;

```
Qy         23 SSAGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTLSAETSSRASTPAGPIPEAETRG 82
              :: |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         13 TNTGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTLSAETSSRASTPAGPIPEAETRG 72

Qy         83 AKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPEGAGMTTVQTITGSDPEEAIFDT 142
              |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db         73 AKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPEGAGMTTVQTITGSDPREAIFDT 132

Qy        143 LCTDDSSEEAKTLTMDILTLAHTSTEAKGLS---------------------------- 173
              |||||||||||||||||||||||||||||||
Db        133 LCTDDSSEEAKTLTMDILTLAHTSTEAKGLSSESSASSDSPHPVITPSRASESSASSDGP 192

Qy        174 ----------------------------SESSASSDGPHPVITPSRASESSASSDGPHPV 205
                                          ||||||||||||||||||||||||||||||||
Db        193 HPVITPSRASESSASSDGLHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPV 252

Qy        206 ITPSRASESSASSDGPHPVITPSWSPGSDVTLLAEALVTVTNIEVINCSITEIETTTSSI 265
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        253 ITPSRASESSASSDGPHPVITPSWSPGSDVTLLAEALVTVTNIEVINCSITEIETTTSSI 312

Qy        266 PGASDIDLIPTEGVKASSTSDPPALPDSTEAKPHITEVTASAETLSTAGTTESAAPHATV 325
              ||||| |||||||||||||||||||||||||||||||||||||||||||||||||| |||
Db        313 PGASDTDLIPTEGVKASSTSDPPALPDSTEAKPHITEVTASAETLSTAGTTESAAPDATV 372

Qy        326 GTPLPTNSATEREVTAPGATTLSGALVTVSRNPLEETSALSVETPSYVKVSGAAPVSIEA 385
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        373 GTPLPTNSATEREVTAPGATTLSGALVTVSRNPLEETSALSVETPSYVKVSGAAPVSIEA 432

Qy        386 GSAVGKTTSFAGSSASSYSPSEAALKNFTPSETPTMDIATKGPFPTSRDPLPSVPPTTTN 445
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        433 GSAVGKTTSFAGSSASSYSPSEAALKNFTPSETPTMDIATKGPFPTSRDPLPSVPPTTTN 492

Qy        446 SSRGTNSTLAKITTSAKTTMKP 467
              ||||||||||||||||||||||
Db        493 SSRGTNSTLAKITTSAKTTMKP 514
```

RESULT 3
Q96KA1
ID Q96KA1 PRELIMINARY; PRT; 487 AA.
AC Q96KA1;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical protein FLJ14408.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Embryo;
RA Isogai T., Ota T., Hayashi K., Sugiyama T., Otsuki T., Suzuki Y.,
RA Nishikawa T., Nagai K., Sugano S., Shiratori A., Sudo H.,
RA Wagatsuma M., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA Takahashi M., Chiba Y., Ishida S., Murakawa K., Ono Y., Takiguchi S.,
RA Watanabe S., Kimura K., Murakami K., Ishii S., Kawai Y., Saito K.,
RA Yamamoto J., Wakamatsu A., Nakamura Y., Nagahari K., Masuho Y.,
RA Ninomiya K., Iwayanagi T.;
RT "NEDO human cDNA sequencing project.";
RL Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AK027314; BAB55035.1; -.
KW Hypothetical protein.
SQ SEQUENCE 487 AA; 50120 MW; 6A60F56465875886 CRC64;

Query Match 84.8%; Score 2060; DB 4; Length 487;
Best Local Similarity 87.1%; Pred. No. 5.2e-104;
Matches 420; Conservative 0; Mismatches 10; Indels 52; Gaps 2;

```
Qy          1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTL 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGCLWGLALPLFFFCWEVGVSGSSAGPSTRRADTAMTTDDTEVPAMTLAPGHAALETQTL 60

Qy         61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SAETSSRASTPAGPIPEAETRGAKRISPARETRSFTKTSPNFMVLIATSVETSAASGSPE 120

Qy        121 GAGMTTVQTITGSDPEEAIFDTLCTDDSSEEAKTLTMDILTLAHTSTEAKGLSSESSASS 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 GAGMTTVQTITGSDPEEAIFDTLCTDDSSEEAKTLTMDILTLAHTSTEAKGLSSESSASS 180

Qy        181 DGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSWSPGSDVTLLAE 240
              |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db        181 DGPHPVITPSRASESSASSDGPHPVITPSRASESSASSDGPHPVITPSWSPGSDVALLAE 240

Qy        241 ALVTVTNIEVINCSITEIETTTSSIPGASDIDLIPTEGVKASSTSDPPALPDSTEAKPHI 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ALVTVTNIEVINCSITEIETTTSSIPGASDIDLIPTEGVKASSTSDPPALPDSTEAKPHI 300

Qy        301 TEVTASAETLSTAGTTESAAPHATVGTPLPTNSATEREVTAPGATTLSGALVTVSRNPLE 360
              ||||||||||
Db        301 TEVTASAETLS---------------------------------------------- 311
```